未治療の局所進行性または転移性肝細胞癌（HCC）患者を対象とした、アテゾリズマブとベバシズマブ（チラゴルマブ併用または非併用）を評価する試験（IMbrave152）

基本情報

NCT ID

NCT05904886

ステータス

実施中（募集終了）

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

687

治験依頼者名

Hoffmann-La Roche

概要

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.

対象疾患

介入

依頼者（Sponsor）

実施施設 (20)